A disruption in anti-tumor response to the IFN γ signaling pathway can inhibit the Janus kinase (JAK) and (STAT) signaling pathway, downregulating PD-L1 expression, and making anti-PD-1 treatment ineffective. This evidence concerns the gene CD274 and neoplasm.